MedPath

Biocells (Beijing) Biotech Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

Phase 2
Recruiting
Conditions
Acute Ischemic Stroke
Interventions
Drug: Placebo
Drug: low-dose BXOS110
Drug: high-dose BXOS110
First Posted Date
2024-03-21
Last Posted Date
2024-03-21
Lead Sponsor
Biocells (Beijing) Biotech Co.,Ltd
Target Recruit Count
300
Registration Number
NCT06322394
Locations
🇨🇳

Yuebei People's Hospital, Shaoguan, Guangdong, China

🇨🇳

Harrison International Peace Hospital, Hengshui, Hebei, China

🇨🇳

The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 21 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.